Company profile IBRX

ImmunityBio Inc
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating na...tural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells. Show More
Quarter analysis & expected interestLast update: February 09 2024 03:56:20.

After 39 days of this quarter the interest is at 84.0. Based on that we can calculate that during remaining 52 days it will total up to 196.0.
ImmunityBio expected interest is significantly lower compared to previous quarter (-51.8%) but similar to same quarter last year.

YearQ1Q2Q3Q4
20199
16
77.8% QoQ
10
-37.5% QoQ
38
280.0% QoQ
2020 28
211.1% YoY -26.3% QoQ
86
437.5% YoY 207.1% QoQ
37
270.0% YoY -57.0% QoQ
171
350.0% YoY 362.2% QoQ
2021 184
557.1% YoY 7.6% QoQ
252
193.0% YoY 37.0% QoQ
196
429.7% YoY -22.2% QoQ
178
4.1% YoY -9.2% QoQ
2022 248
34.8% YoY 39.3% QoQ
278
10.3% YoY 12.1% QoQ
258
31.6% YoY -7.2% QoQ
184
3.4% YoY -28.7% QoQ
2023 260
4.8% YoY 41.3% QoQ
395
42.1% YoY 51.9% QoQ
262
1.6% YoY -33.7% QoQ
407
121.2% YoY 55.3% QoQ
2024 84
-67.7% YoY -79.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ImmunityBio search interestLast update: February 09 2024 03:56:20.
Correlation coefficient between keyword and revenue is -0.22
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 03:56:22.

The average 5 years interest of ImmunityBio was 13.72 per week.
The last year interest of ImmunityBio compared to the last 5 years has changed by 82.65%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 1437.42%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio ImmunityBio stock to provide analysis

Correlation between past revenue and ImmunityBio ImmunityBio stock search interest

There is not enough data for ImmunityBio ImmunityBio stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio ImmunityBio stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio company to provide analysis

Correlation between past revenue and ImmunityBio company search interest

There is not enough data for ImmunityBio company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 03:56:29.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
ImmunityBio news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201987
99
13.8% QoQ
231
133.3% QoQ
171
-26.0% QoQ
2020 84
-3.4% YoY -50.9% QoQ
39
-60.6% YoY -53.6% QoQ
95
-58.9% YoY 143.6% QoQ
19
-88.9% YoY -80.0% QoQ
2021 159
89.3% YoY 736.8% QoQ
134
243.6% YoY -15.7% QoQ
83
-12.6% YoY -38.1% QoQ
58
205.3% YoY -30.1% QoQ
2022 89
-44.0% YoY 53.4% QoQ
53
-60.4% YoY -40.4% QoQ
24
-71.1% YoY -54.7% QoQ
57
-1.7% YoY 137.5% QoQ
2023 179
101.1% YoY 214.0% QoQ
210
296.2% YoY 17.3% QoQ
103
329.2% YoY -51.0% QoQ
133
133.3% YoY 29.1% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ImmunityBio news search interestLast update: February 09 2024 03:56:28.
Correlation coefficient between keyword and revenue is 0.26
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 03:56:31.

The average 5 years interest of ImmunityBio news was 8.07 per week.
The last year interest of ImmunityBio news compared to the last 5 years has changed by 38.66%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -6.28%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio vaccine to provide analysis

Correlation between past revenue and ImmunityBio vaccine search interest

There is not enough data for ImmunityBio vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio cancer therapy to provide analysis

Correlation between past revenue and ImmunityBio cancer therapy search interest

There is not enough data for ImmunityBio cancer therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio cancer therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio clinical trials to provide analysis

Correlation between past revenue and ImmunityBio clinical trials search interest

There is not enough data for ImmunityBio clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio therapies to provide analysis

Correlation between past revenue and ImmunityBio therapies search interest

There is not enough data for ImmunityBio therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ImmunityBio immunotherapy to provide analysis

Correlation between past revenue and ImmunityBio immunotherapy search interest

There is not enough data for ImmunityBio immunotherapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ImmunityBio immunotherapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for IBRX
Earnings date: 2024-02-28 After close
Company name: ImmunityBio Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-21T11:30:00Z

BusinessWire
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

2026-10-16T15:49:00Z

BusinessWire
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

2026-10-15T16:41:20.455551085Z

Analyst Upgrades
Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14

2026-10-15T10:29:14.598410695Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

2026-10-14T20:18:00Z

BusinessWire
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

2026-10-08T12:30:00Z

BusinessWire
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

2026-09-14T07:30:00-07:00

GlobeNewswire
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

2026-08-10T13:00:00Z

BusinessWire
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

2026-08-04T11:30:00Z

BusinessWire
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

2026-07-29T22:45:00Z

BusinessWire
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

2026-06-08T13:01:00Z

GlobeNewswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

2026-06-03T13:28:24Z

GlobeNewswire
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

2026-06-02T10:37:04Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

2026-06-01T17:51:00Z

BusinessWire
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

2026-05-29T09:00:00-04:00

PR Newswire
The $13 Million Company Teaching the Immune System to Hunt Cancer